# Oncolytics Biotech Secures Patent Extensions

> Oncolytics Biotech extends cancer immunotherapy patent protection to late 2040s with new intellectual property updates.
- Title: Oncolytics Biotech Secures Patent Extensions · Financialpost
- Summary: Oncolytics Biotech extends cancer immunotherapy patent protection to late 2040s with new intellectual property updates. Oncolytics Biotech secures method of…
- Keywords: oncolytics, pelareorep, immunotherapy, patent, composition of matter, next generation, nasa, money, business, Biotech, Secures, Extensions
- Source: Financialpost — https://financialpost.com/globe-newswire/oncolytics-biotech-secures-patent-protection-to-late-2040s-and-provides-intellectual-property-portfolio-update
- Read time: 1 min
- Topics: oncolytics, pelareorep, immunotherapy, patent, composition of matter, next generation, nasa, money, business
## Patent Update
Oncolytics Biotech provides intellectual property strategy update with new method of use patents for pelareorep immunotherapy.

> Oncolytics Biotech Inc. (Nasdaq: ONCY) provides update on intellectual property strategy
## Global Patent Issuance
New method of use patent for pelareorep as cancer immunotherapy issued in several countries with U.S. patent expected soon.

> A new method of use patent covering pelareorep as an immunotherapy for the treatment of cancer has been issued in several countries
## Pending Applications
Three patent applications pending including two method of use patents with one expected to become U.S. Track One application this quarter.

> Oncolytics has three patent application families pending, including multiple method of use patents
## Track One Application
Company expects to convert one pending application into U.S. Track One application for prioritized examination this quarter.

> This quarter, the Company expects to convert one of these pending applications into a U.S. application submitted with a request for Track One prioritized examination
## Next Generation Pelareorep
Company working with academic partner on modified pelareorep for potential enhanced efficacy with up to 20 years of patent protection.

> In parallel, Oncolytics is working with an academic partner on a modified form of pelareorep that the Company refers to as "next generation" pelareorep
## Patent Strategy
Oncolytics extends patent protection through late 2040s with existing manufacturing protection through 2044.

> The Company expects this work to support the addition of a new composition of matter patent to its portfolio, with the potential for up to 20 years of patent protection measured from the applicable filing date
## Key takeaway

Oncolytics Biotech secures method of use patents for pelareorep immunotherapy and composition of matter patents for next generation version, extending patent protection through late 2040s.